此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions

2026年11月4日 更新者:Aponia Laboratories, Inc.

Randomized, Controlled, Multi-center Trial to Evaluate the Efficacy, Tolerability, and Safety of an S-Ibuprofen Gel vs. Placebo in the Local Symptomatic and Short-Term Treatment of Pain in Acute Contusions of the Soft Tissues Following Blunt Trauma

Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%

研究概览

详细说明

The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in treatment of pain in acute contusions of the soft tissues following blunt trauma.

研究类型

介入性

注册 (估计的)

240

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bonn、德国、53113
        • 招聘中
        • Dr. med Jürgen Ulrich Schaale-Maas
        • 接触:
      • Bonn、德国、53121
        • 招聘中
        • Orthopädische Praxis-Ebert
        • 接触:
          • Eduart Ebert, Dr. med.
          • 电话号码:+49 173 7038059
          • 邮箱:ebert.e@web.de
      • Gilching、德国、82205
        • 招聘中
        • Dr. Helmut Pabst
        • 接触:
    • Oregon
      • Bend、Oregon、美国、97702
        • 招聘中
        • Northwest Foot Care - Amanda Westfall McCarty
        • 接触:
      • Bend、Oregon、美国、97702
        • 招聘中
        • Northwest Foot Care - Bryan Wilhelm
        • 接触:
      • Bend、Oregon、美国、97702
        • 招聘中
        • Northwest Foot Care - Hayden Bush
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Acute soft-tissue injury/contusion.
  2. Enrollment within 6 hours of the injury.
  3. Baseline NRS score for POM of injured location >5 score points on an 11-point NRS.
  4. Size of injury, as assessed by the investigator, ≥25 cm2 and ≤120 cm2
  5. Adult male or female patients aged ≥18 years.
  6. Having given written informed consent.
  7. Satisfactory health as determined by the investigator based on medical history and physical examination.

Exclusion Criteria:

  1. Significant concomitant injury in association with the acute injury; e.g., fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound.
  2. Excessively hairy skin at application site, cutting the hair in the injured site prior to gel application will qualify for inclusion.
  3. Current skin disorder or shaving hair at application site.
  4. History of excessive sweating/hyperhidrosis inclusive of application site.
  5. Treatment with topical or systemic NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study.
  6. Intake of long-acting NSAIDs or application of topical medication since the injury (rest-ice-compression-elevation [RICE] is allowed).
  7. Participation in a clinical study within 30 days before inclusion in the study or concomitantly.
  8. Positive drug or alcohol screen or evidence of drug or alcohol abuse in the opinion of the investigator.
  9. Pregnant or lactating or intending to become pregnant during the study.
  10. Individuals of reproductive potential who do not agree to use of an acceptable birth control method throughout the study, when engaging in any sexual activity that comes with a risk of pregnancy.
  11. History of any allergy or hypersensitivity (e.g., anaphylaxis, urticaria/hives, rhinitis, skin reaction, asthma, angioedema, or other allergic symptoms) to acetaminophen, ibuprofen, other NSAIDs, or to 1 of the excipients of the gel.
  12. History of severe cutaneous adverse reactions to any medication, such as Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis.
  13. Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of S-ibuprofen gel 5%.
  14. History of previous significant injury to the same extremity within 6 months.
  15. Patients with a disease affecting the same area, such as synovitis, rheumatoid arthritis, arthrosis, etc.
  16. Patients experiencing symptoms of an infectious disease including swelling of any joint of the affected area.
  17. Patients having an ongoing painful condition associated with the injury/contusion.
  18. Patients who had surgery of the affected area within 1 year of study entry.
  19. Patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study; including patients with a history of gastrointestinal bleeding, significant cardiovascular, liver, or renal disease).
  20. Patients with a blood coagulation disorder.
  21. Patients who use any impermissible medication (eg. systemic or topical NSAIDs, analgesics (other than paracetamol), opiods, corticosteroids (except for topical treatment of bronchial asthma, heparin, or psychotropic agents)
  22. Patients who participated in previous clinical studies of S-ibuprofen gel 5% and patients of the same household.
  23. Patients who are related to those persons involved directly or indirectly with the conduct of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:S-Ibuprofen Topical Gel 5%

S-Ibuprofen Topical Gel 5% applied once per day to the affected injury site

Topical gel containing active ingredient S-ibuprofen

安慰剂比较:Vehicle Topical Gel

Placebo Gel applied once per day to the affected injury site

Placebo gel matching the active comparator in conposition and appearance without the active ingredient

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt trauma
大体时间:0-24 hours

Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for pain-on-movement at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

0-24 hours

次要结果测量

结果测量
措施说明
大体时间
Time to first perceptible pain relief based on direct questions to the patient and what they consider perceptible pain relief
大体时间:From time 0 every 24 hours up to 7 days

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 every 24 hours up to 7 days
Time to onset of meaningful pain relief based on direct questions to the patient and what they consider meaningful pain relief
大体时间:From time 0 to end of study (day 7)

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 to end of study (day 7)
Time gap between first perceptible pain relief and meaningful pain relief based on direct questions to the patient
大体时间:From time 0 to end of study (day 7)

Calculated as a difference to reach perceptible vs meaningul pain relief.

From time 0 to end of study (day 7)
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for spontaneous pain-on-movement (sPOM) at 24 hours
大体时间:At 24 hours

Recorded in patient diary based on NRS scores for sPOM at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At 24 hours
Change from baseline for pain-at-rest (PAR) measured by numerical rating scale (NRS) at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for PAR at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for pain-on-movement (POM) measured at Visit 3, Visit 4, Visit 5, and Visit 6
大体时间:At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for POM. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for spontaneous pain-on-movement measured at 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours
大体时间:6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration

When possible, recorded in patient diary. NRS scale 0-10, 0=no pain, 10=worst possible pain.

6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
Pain-on-movement at the injured site recorded on a numerical rating scale (NRS) scale in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Sum of pain intensity differences (SPIDs) for pain-on-movement at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Baseline-adjusted area under the curve (AUC) for pain-on-movement at the injured site recorded on a numerical rating scale (NRS) in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Pain at rest measured by a numerical rating scale (NRS) at baseline at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Time-specific pain intensity difference for spontaneous pain-on-movement at all time points
大体时间:Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
大体时间:Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study.NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for spontaneous pain on movement at all time points
大体时间:Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
大体时间:Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete pain relief (Score = 0 pain)
大体时间:Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain-on-movement (Score = 0 pain)
大体时间:Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain at rest (Score = 0 of pain)
大体时间:Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to the first request of rescue medication within the first 24 hours
大体时间:Time 0 to 24 hours

If applicable

Time 0 to 24 hours
Proportion of patients taking rescue medication per dosing interval and during the entire evaluation period
大体时间:Time 0 to end of study (day 7)

If applicable

Time 0 to end of study (day 7)
Responder rate (defined as the number of patients achieving 50% reduction from baseline in the NRS score for pain-on-movement at 24 hours)
大体时间:Time 0 to 24 hours

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to 24 hours
Global efficacy assessment by investigator (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Global efficacy assessments by patient (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
大体时间:At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Overall dose of rescue medication
大体时间:Time 0 to end of study (Day 7)

Rescue medication use will be assessed at every visit except Visit 1

Time 0 to end of study (Day 7)
Local tolerability at every visit except V1
大体时间:Time 0 to end of study (day 7)

Examination for presence of erythema (0-3, 0 = none; 3 = severe), edema (0-3, 0 = none; 3 = severe), papiculation/vesiculation (0-3, 0 = none; 3 = severe), pruritus (NRS scale 0-10; 0 = no itch, 10 = worst possible itch), burning (NRS scale 0-10; 0 = no itch, 10 = worst possible itch)

Time 0 to end of study (day 7)
Blood pressure exam at V1 and V6
大体时间:At Visit 1 (time 0) and 6 (168 hours)

Systolic/diastolic blood pressure

At Visit 1 (time 0) and 6 (168 hours)
Adverse events at every visit
大体时间:Time 0 to end of study (day 7)
Time 0 to end of study (day 7)
Examination of pulse at V1 and V6
大体时间:At Visit 1 (time 0) and 6 (168 hours)

Pulse measured as beats per minute

At Visit 1 (time 0) and 6 (168 hours)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月8日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2026年10月25日

首先提交符合 QC 标准的

2026年11月4日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • AP-009
  • 2025 (美国 NIH 拨款/合同)
  • 2025-524451-31-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅